Atlas Trials

Milestone Pharmaceuticals Inc.

9 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Milestone Pharmaceuticals Inc.

RecordFirmDate
ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 (NCT06716021)Milestone Pharmaceuticals Inc.2027-01-01
The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) (NCT05763953)Milestone Pharmaceuticals Inc.2023-12-11
Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia (NCT04952610)Milestone Pharmaceuticals Inc.2021-12-13
ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2 (NCT04467905)Milestone Pharmaceuticals Inc.2020-11-19
Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303 (NCT04072835)Milestone Pharmaceuticals Inc.2019-09-23
Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302 (NCT03635996)Milestone Pharmaceuticals Inc.2018-12-10
Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT). (NCT03464019)Milestone Pharmaceuticals Inc.2018-06-18
The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry. (NCT03353610)Milestone Pharmaceuticals Inc.2017-10-16

Track Milestone Pharmaceuticals Inc. automatically

Every clearance here is in the API, with alerts when new ones post.